Accessibility Menu
TetraLogic Pharmaceuticals logo

TetraLogic Pharmaceuticals(OTC) TLOG

Market Cap$2.40KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2013)-100%
5 Year-99%
1 Year+0%
1 Month+150%
$0.00
+0.00%
+0.00Today
TetraLogic Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 0.002026-08-12
TetraLogic Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+9,900%USD 0.002026-08-05
1 month+150%USD 0.002026-05-14
3 month+150%USD 0.002026-05-14
Year to date+0%USD 0.002025-12-29
1 year+0%USD 0.002025-07-30
3 year+0%USD 0.002023-07-25
5 year-99.12%USD 0.012021-08-13
Since inception-100%USD 7.002013-12-12

TetraLogic Pharmaceuticals Financials at a Glance

Market Cap

$2.40KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$45.76M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

23.94 (High)

Price

$0.00

Volume

900

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Feb 28, 2025

TLOG News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About TetraLogic Pharmaceuticals

TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical firm focused on developing small-molecule treatments for cancer and infectious diseases. The company is advancing two key drug candidates, birinapant and SHAPE, aimed at addressing significant medical needs.

Products and Services
  • Birinapant: A SMAC mimetic promoting apoptosis in cancer cells
  • SHAPE: An HDAC inhibitor for treating early-stage cutaneous T-cell lymphoma
  • Research collaboration with Walter and Eliza Hall Institute for infectious diseases
Growth Outlook
  • Strong pipeline with two clinical-stage drug candidates targeting unmet medical needs
  • Collaboration with leading research institute enhances innovation potential
  • Focus on oncology and infectious diseases aligns with market demand
Financial Highlights
  • Recent quarterly net income of -$8.63 million reflects ongoing R&D investments
  • Cash and short-term investments totaled $5.88 million as of September 30, 2016
  • Current ratio of 6.00 indicates strong liquidity position
TetraLogic Pharmaceuticals Corporation operates in the biotechnology sector, emphasizing innovative solutions for serious health conditions. The company's lead candidates, birinapant and SHAPE, are positioned to address critical gaps in treatment options, particularly in oncology. The collaboration with the Walter and Eliza Hall Institute further strengthens its research capabilities, potentially leading to breakthroughs in infectious disease treatment. Financially, TetraLogic has been investing heavily in research and development, as evidenced by the recent quarterly net income loss. However, the liquidity position remains robust, with a current ratio of 6.00, indicating the ability to cover short-term liabilities. The cash reserves, while diminished, provide a foundation for continued operations and development efforts. Overall, TetraLogic Pharmaceuticals presents a compelling opportunity for investors interested in the biotechnology space, particularly those focused on innovative cancer and infectious disease therapies.
AI Generated • Aug 5, 2026

Industry

Biotechnology

Headquarters

Malvern, PA 19355, US

TLOG Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-408.63%

Return on Capital

-201.41%

Return on Assets

-87.64%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.40KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

24.46M

Volume

900

Avg. Volume

33.968

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$36.53M

EBITDA

-$36.09M

Operating Cash Flow

-$23.88M

Capital Expenditure

-$666.00

Free Cash Flow

-$23.88M

Cash & ST Invst.

$5.89M

Total Debt

$30.81M

TetraLogic Pharmaceuticals Performance Analysis

TetraLogic Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42015-12-31N/A
Q12016-03-31N/A
Q22016-06-30N/A
Q32016-09-30N/A
TetraLogic Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42015-12-31-23.1%
Q12016-03-3120.3%
Q22016-06-3033.3%
Q32016-09-30-2.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q3 2016YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$2.40KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$82.76

N/A

Employees

29

N/A

Net Income

-$8.63M

+30.9%

EBITDA

-$9.18M

+0.6%

Quarterly Fundamentals

Name
Q3 2016YOY CHG

Total Cash

$5.89M

-80.1%

Total Debt

$30.81M

+6.9%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$30.79M

+6.9%

Short Term Debt

$0.00

N/A

Return on Assets

-87.64%

N/A

Return on Invested Capital

-74.54%

N/A

Free Cash Flow

-$2.79M

+63.7%

Operating Cash Flow

-$2.79M

+63.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KLDOKaleido Biosciences, Inc.
$0.00+0.00%
CALACalithera Biosciences, Inc.
$0.00+0.00%
BXRXQBaudax Bio, Inc.
$0.00+0.00%
TNGNQTengion, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.77+0.10%
IBITiShares Bitcoin Trust
$43.68+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$10.41+0.06%
MARAMara Holdings
$11.26+0.01%

Questions About TLOG

What is the current price of TetraLogic Pharmaceuticals?

TetraLogic Pharmaceuticals is trading at $0.00 per share.

What is the 52-week range for TetraLogic Pharmaceuticals?

Over the past 52 weeks, TetraLogic Pharmaceuticals has traded between $0.00 and $0.00.

How much debt does TetraLogic Pharmaceuticals have?

TetraLogic Pharmaceuticals total debt is unavailable.

How much cash does TetraLogic Pharmaceuticals have on hand?

TetraLogic Pharmaceuticals does not have cash on hand data available.

What is TetraLogic Pharmaceuticals’s dividend yield?

TetraLogic Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.